Felix Bayerl
Overview
Explore the profile of Felix Bayerl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elewaut A, Estivill G, Bayerl F, Castillon L, Novatchkova M, Pottendorfer E, et al.
Nature
. 2024 Nov;
637(8046):716-725.
PMID: 39604727
The tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses. Within the tumour microenvironment, CD8 T cells undergo full effector differentiation and acquire cytotoxic anti-tumour functions...
2.
Pedde A, Kim H, Donakonda S, Baumann T, Bayerl F, Meiser P, et al.
Cell Rep
. 2024 Nov;
43(11):114855.
PMID: 39541209
Natural killer (NK) cells are critical for anti-metastatic immunity and can eliminate metastasizing tumor cells within circulation and sites of metastatic seeding. Here, we show that disseminated tumor cells (DTCs)...
3.
Lacher S, Dorr J, de Almeida G, Honninger J, Bayerl F, Hirschberger A, et al.
Nature
. 2024 Apr;
629(8011):417-425.
PMID: 38658748
Cancer-specific TCF1 stem-like CD8 T cells can drive protective anticancer immunity through expansion and effector cell differentiation; however, this response is dysfunctional in tumours. Current cancer immunotherapies can promote anticancer...
4.
Meiser P, Knolle M, Hirschberger A, de Almeida G, Bayerl F, Lacher S, et al.
Cancer Cell
. 2023 Jul;
41(8):1498-1515.e10.
PMID: 37451271
Type 1 conventional dendritic cells (cDC1) can support T cell responses within tumors but whether this determines protective versus ineffective anti-cancer immunity is poorly understood. Here, we use imaging-based deep...
5.
Bayerl F, Meiser P, Donakonda S, Hirschberger A, Lacher S, Pedde A, et al.
Immunity
. 2023 Jun;
56(6):1341-1358.e11.
PMID: 37315536
Type 1 conventional dendritic cells (cDC1s) are critical for anti-cancer immunity. Protective anti-cancer immunity is thought to require cDC1s to sustain T cell responses within tumors, but it is poorly...
6.
Eckfeld C, Schoeps B, Haussler D, Fradrich J, Bayerl F, Bottcher J, et al.
J Cell Biol
. 2023 Jan;
222(2).
PMID: 36629908
The emerging cytokine tissue inhibitor of metalloproteinases-1 (TIMP-1) correlates with the progression of inflammatory diseases, including cancer. However, the effects of TIMP-1 on immune cell activation and underlying molecular mechanisms...
7.
Bayerl F, Bejarano D, Bertacchi G, Doffin A, Gobbini E, Hubert M, et al.
Eur J Immunol
. 2023 Jan;
53(11):e2249923.
PMID: 36623939
This article is part of the Dendritic Cell Guidelines article series, which provides a collection of state-of-the-art protocols for the preparation, phenotype analysis by flow cytometry, generation, fluorescence microscopy, and...
8.
Schoeps B, Eckfeld C, Fluter L, Keppler S, Mishra R, Knolle P, et al.
J Biol Chem
. 2021 Aug;
297(3):101072.
PMID: 34391782
Multifunctionality of tissue inhibitor of metalloproteinases-1 (TIMP-1) comprising antiproteolytic as well as cytokinic activity has been attributed to its N-terminal and C-terminal domains, respectively. The molecular basis of the emerging...
9.
Dudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, et al.
Nature
. 2021 May;
593(7860):E14.
PMID: 33972788
No abstract available.
10.
Dudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, et al.
Nature
. 2021 Mar;
592(7854):444-449.
PMID: 33762736
Nonalcoholic steatohepatitis (NASH) is a manifestation of systemic metabolic disease related to obesity, and causes liver disease and cancer. The accumulation of metabolites leads to cell stress and inflammation in...